Research Paper Volume 12, Issue 6 pp 5183—5194

LncRNA AGAP2-AS1 augments cell viability and mobility, and confers gemcitabine resistance by inhibiting miR-497 in colorectal cancer

Figure 1. AGAP2-AS1 was overexpressed in CRC tissues. (A) Relative expression levels of AGAP2-AS1 in 116 paired CRC tissues and paired noncancerous tissues were quantified by qRT-PCR. (B) AGAP2-AS1 was upregulated (> 2-fold) in 48.3% of the CRC tissues. (C, D) Kaplan–Meier survival analysis of the OS and DFS in CRC patients with low or high AGAP2-AS1 expression.